Acetaminophen mechanism of action: Analgesic may work by inhibiting COX-3 activity in brain and spinal cord, N. V. Chandrasekharan, et al., Brigham Young University, report in online Proceedings of the National Academy of Sciences posted Sept. 19. BYU researchers say they found a third distinct COX enzyme, which they named COX-3, derived from same gene as COX-1. Researchers tested common analgesic/antipyretic drugs and NSAIDS for their ability to inhibit COX -1, -2 and -3 activity in presence of exogenously added arachidonic acid at two concentrations. "At the higher concentration of substrate, only COX-3 was inhibited by acetaminophen. Moreover, COX-3 was significantly more sensitive to acetaminophen than either COX-1 or- 2 at the lower substrate concentration," Chandrasekharan et al. report. Researchers say their findings suggest that "highly selective inhibitors can be made for COX-3"...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
The FDA employees with reduction-in-force notice rescissions include some who work on user fee negotiations, but staff still subject to RIFs will not officially separate from the agency this week due to ongoing legal challenges.
Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.
